Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on HeFH (Mar 2021)

Posted by Matt Breese on Mar 26, 2021

Find me on:

According to our recent payer coverage analysis for HeFH treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for HeFH treatments shows that under the pharmacy benefit, about 66% of the lives under commercial formularies are covered with utilization management

MMIT-Reality Check-HeFH-1Q2021Data snapshot as of Q1 2021

Trends: In February 2020, the FDA approved Esperion Therapeutics, Inc.’s Nexletol (bempedoic acid) tablet, a once-daily, non-statin LDL-cholesterol-lowering medicine, for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C. 

To read the full Reality Check on HeFH with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing